Treatment of facial lipoatrophy with polymethylmethacrylate among patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): impact on the quality of life.

Autor: Quintas RC; Plastic Surgery Department, University of Pernambuco, Recife, Brazil., de França ER, de Petribú KC, Ximenes RA, Quintas LF, Cavalcanti EL, Kitamura MA, Magalhães KA, Paiva KC, Filho DB
Jazyk: angličtina
Zdroj: International journal of dermatology [Int J Dermatol] 2014 Apr; Vol. 53 (4), pp. 497-502. Date of Electronic Publication: 2014 Mar 06.
DOI: 10.1111/ijd.12400
Abstrakt: Background: The lipodystrophy syndrome is characterized by selective loss of subcutaneous fat on the face and extremities (lipoatrophy) and/or accumulation of fat around the neck, abdomen, and thorax (lipohypertrophy). The aim of this study has been to assess the impact of polymethylmethacrylate facial treatment on quality of life, self-perceived facial image, and the severity of depressive symptoms in patients living with HIV/AIDS.
Methods: A non-randomized before and after interventional study was developed. Fifty-one patients underwent facial filling. The self-perceived quality of life, facial image, and degree of depressive symptoms were measured by the Short-Form 36 and HIV/AIDS--Targeted quality of life questionnaires, by a visual analogue scale and by the Beck depression inventory, respectively, before and three months after treatment.
Results: Six of the eight domains of Short-Form 36 and eight of the nine dimensions of the HIV/AIDS--Targeted quality of life questionnaires, together with the visual analogue scale and by the Beck depression inventory scores, revealed a statistically significant improvement. The only adverse effects registered were edema and ecchymosis.
Conclusion: The treatment of facial lipoatrophy improved the self-perceived quality of life and facial image as well as any depressive symptoms among patients with HIV/AIDS.
(© 2014 The International Society of Dermatology.)
Databáze: MEDLINE
Externí odkaz: